About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.
With a direct link to the Clinical Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.
In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.
IP: Miquel Vila Bover Collaborators: Jorge Hernández Vara, Joan Compte Barrón, Marta Martínez Vicente, Jordi Bove Badell, Eddie Pradas Gracia, Maria Camprodon Gomez, Camille Guillard Sirieix, Marina Lorente Picón, Laura Castillo Ribelles, Oriol de Fabregues-Boixar Nebot, Javier Hoyo Pérez, Ariadna Laguna Tuset, Thais Cuadros Arasa, Jordi Riera Heredia, David Ramos Vicente, Marta Montpeyó Garcia-Moreno, Helena Xicoy Cortada, Alba Nicolau Vera, Marta González Sepúlveda, Joana Margalida Cladera Sastre, Annabelle Parent, Daniela Samaniego Toro Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 40000 Reference: 2021 SGR 00784 Duration: 01/01/2022 - 31/12/2024
IP: Marta Martínez Vicente Collaborators: José Antonio Arranz Amo, Eddie Pradas Gracia, Laura Castillo Ribelles, Clara Carnicer Cáceres, David Moreno Martinez, Jordi Riera Heredia, Marta Montpeyó Garcia-Moreno, Pablo Castillo Sánchez Funding agency: Fundació "La Caixa" Funding: 249950 Reference: HR22-00602 Duration: 01/11/2022 - 31/10/2025
IP: Francisco Rodríguez Frias Collaborators: - Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 157300 Reference: PID2021-126447OB-I00 Duration: 01/09/2022 - 01/09/2025
IP: Josep Quer Sivila Collaborators: Sergi Colomer Castell, Lluís Viladomiu Catà, Damir Garcia Cehic, Maria Piñana Moro, Pablo Gabriel Medina, Arnau Llauradó Gayete, Carolina Campos Martinez, Alejandra Gonzalez Sánchez Funding agency: Instituto de Salud Carlos III Funding: 292820 Reference: PI22/00258 Duration: 01/01/2023 - 31/12/2025
PMID: 37183562 Journal: EUROPEAN JOURNAL OF NEUROLOGY Year: 2023 Reference: Eur J Neurol. 2023 May 14. doi: 10.1111/ene.15866. Impact factor: Publication type: Paper in international publication Authors: Chuquisana, Omar; Comabella, Manuel; Ferrer, Roser; Fissolo, Nicolas; Gil-Varea, Elia; Giralt, Marina; Lunemann, Jan D; Malhotra, Sunny; Midaglia, Luciana; Montalban, Xavier et al. DOI: 10.1111/ene.15866
PMID: 37073757 Journal: Nutricion Hospitalaria Year: 2023 Reference: Nutr Hosp. 2023 Apr 11. doi: 10.20960/nh.04436. Impact factor: Publication type: Paper in international publication Authors: Albertos, Raquel; Barquin, Raquel; Berlana, David; Cea, Cristina; Lopez-Hellin, Juan; Montoro-Ronsano, J Bruno; Pau-Parra, Alba; Zabalegui, Alba et al. DOI: 10.20960/nh.04436
PMID: 37833106 Journal: MEDICINA CLINICA Year: 2023 Reference: Med Clin (Barc). 2023 Oct 11:S0025-7753(23)00552-3. doi: 10.1016/j.medcli.2023.08.010. Impact factor: Publication type: Other (letters to the editor, abstracts, corrigendum, etc.) Authors: Andrade, Fernanda; Cardona, Victoria; Duran-Lara, Esteban F; Galvan-Blasco, Paula; Gil-Serrano, Johana; Lobos G, Olga; Rafael, Diana; Vijayakumar, Sekar et al. DOI: 10.1016/j.medcli.2023.08.010
PMID: 37870976 Journal: NEW ENGLAND JOURNAL OF MEDICINE Year: 2023 Reference: N Engl J Med. 2023 Oct 21. doi: 10.1056/NEJMoa2306441. Impact factor: Publication type: Paper in international publication Authors: Agrawal, Trishala; Bhattacharya, Archan; Blanco, Ana; Boyer, Michael; Cheng, Susanna; Cho, Byoung Chul; Cruz, Xavier de la; Diez, Orland; Felip, Enriqueta; Feliubadalo, Lidia et al. DOI: 10.1056/NEJMoa2306441
The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.
In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.
During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.
